Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib
In this week’s View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation (AFib). Subscribe to Eagle’s Eye View
--------
8:34
Weight Management in Pregnancy and CVD Risk; Impact of Statins Plus Ezetimibe Post-MI; PARTNER-3 Study 5-year Results
In this week’s View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the echocardiographic outcomes at five years. Subscribe to Eagle’s Eye View
--------
6:52
Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs)
In this week’s View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores OCEANIC-AF, a study that analyzes the differences in outcomes in patients with and without prior use of oral anti-coagulants (OACs). Subscribe to Eagle’s Eye View
--------
7:26
Key Takeaways from ACC.25 Major Trials and Presentations
In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including: Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI) DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI) STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE) Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients. Subscribe to Eagle’s Eye View
Su Eagle's Eye View: Your Weekly CV Update From ACC.org
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
Italia